

Management of chronic daily headache with focus on botulinum toxin type - Nigora Kadyrkhodjayeva - Tashkent Medical Academy, Uzbekistan

Nigora Kadyrkhodjayeva

Tashkent Medical Academy, Uzbekistan

Goal:

The purpose of the study was to review the efficacy, safety and tolerability of botulinum toxin A (BTX-A) as a prophylactic treatment in adults with chronic daily headache (CDH).

Material and methods:

The study involved 100 patients with CDH comparing between two groups of patients. Group I, 54 patients (31 women and 23 men) treated by BTX-A, and group II, 46 patients (27 women and 21 men) treated with the classical method, with an average age of 35 ± 9 years.

Results: After 3 months headache severity in group I: 2 (3,7%) patients had no changes, 7 (12,9%) patients with less than 50 percent reduction in pain, 23 (42,6%) reported 70 to 95 percent pain relief, and 22 (40,8%) had complete relief. Group II: 12 (26,1%) patients had no changes, 16 (34,8%) patients with less than 50 percent reduction in pain, 10 (21,7%) reported 70 to 95 percent pain relief, and 8 (17,4%) had complete relief. The mean change from baseline frequency of headaches ranged from 3 ± 1 headaches per 30-day period in group I and 7 ± 2 headaches in group II.

Conclusion:

In this study, BTX-A injections have been shown to be safe, well-tolerated, not any treatment-related serious adverse events reported. BTX-A injections recommended optimizing clinical outcomes for patients with CDH without using other prophylactic medications.

Speaker Publications:

1. Kadyrkhodjayeva N (2017) "A new look at the problem of Tension type headache and its treatment methods". *New day in Medicine* 2 (18): 38.
2. Prokhorova A, Kadyrkhodjayeva N (2017) "Use of Botulotoxin type A in the treatment of primary headache". *Journal of research in health science* 1(1): 50.
3. Prokhorova A, Kadyrkhodjayeva N (2018) "Optimization of management of primary chronic headache with the use of botulotoxin A". *EuroSciCon Conference on Neurology & Neurological Disorders*.
4. Prokhorova A, Kadyrkhodjayeva N (2019) "Botulotoxin therapy of patients with primary chronic headaches" (Review).
5. Kadyrkhodjayeva N, Prokhorova A (2019) "Use of botulinum toxin type A to optimize the treatment of primary chronic headaches" *Clinical Practice Guideline, Uzbekistan*.